Modified gellan gum hydrogels for tissue engineering applications by Ferris, Cameron J et al.
University of Wollongong 
Research Online 
Faculty of Science, Medicine and Health - 
Papers: part A Faculty of Science, Medicine and Health 
2013 
Modified gellan gum hydrogels for tissue engineering applications 
Cameron J. Ferris 
University of Wollongong, cjf146@uowmail.edu.au 
Kerry J. Gilmore 
University of Wollongong, kerryg@uow.edu.au 
Gordon G. Wallace 
University of Wollongong, gwallace@uow.edu.au 
Marc in het Panhuis 
University of Wollongong, panhuis@uow.edu.au 
Follow this and additional works at: https://ro.uow.edu.au/smhpapers 
 Part of the Medicine and Health Sciences Commons, and the Social and Behavioral Sciences 
Commons 
Recommended Citation 
Ferris, Cameron J.; Gilmore, Kerry J.; Wallace, Gordon G.; and in het Panhuis, Marc, "Modified gellan gum 
hydrogels for tissue engineering applications" (2013). Faculty of Science, Medicine and Health - Papers: 
part A. 341. 
https://ro.uow.edu.au/smhpapers/341 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Modified gellan gum hydrogels for tissue engineering applications 
Abstract 
Gellan gum is an anionic linear polysaccharide well known for its use as a multi-functional gelling, 
stabilising and suspending agent in a variety of foods and personal care products. In this Highlight, we 
explore the recently established directions for gellan gum hydrogels as materials for applications in tissue 
engineering. We highlight that modified gellan gum will be well suited for this purpose, providing that a 
number of remaining challenges are addressed. 
Keywords 
tissue, engineering, applications, hydrogels, modified, gum, gellan 
Disciplines 
Medicine and Health Sciences | Social and Behavioral Sciences 
Publication Details 
Ferris, C. J., Gilmore, K. J., Wallace, G. G. & in het Panhuis, M. (2013). Modified gellan gum hydrogels for 
tissue engineering applications. Soft Matter, 9 (14), 3705-3711. 





This journal is © The Royal Society of Chemistry [year] [journal], [year], [vol], 00–00  |  1 
Modified gellan gum hydrogels for tissue engineering applications 
Cameron J. Ferris,a,b Kerry J. Gilmore,b Gordon G. Wallace,b and Marc in het Panhuisa,b,* 
Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX 
DOI: 10.1039/b000000x 
Gellan gum is an anionic linear polysaccharide well known for its use as a multi-functional gelling, 5 
stabilising and suspending agent in a variety of foods and personal care products. In this Highlight, we 
explore the recently established directions for gellan gum hydrogels as materials for applications in tissue 
engineering. We highlight that modified gellan gum will be well suited for this purpose, providing that a 
number of remaining challenges are addressed.
1. Introduction 10 
The biopolymer gellan gum (GG) was identified in 1978 by CP 
Kelco (San Diego, USA) during a large scale screening operation 
to identify polysaccharides from soil and water bacteria with 
useful rheological properties1.  Since then it has found wide 
application mainly as a multi-functional gelling, stabilising and 15 
suspending agent in a variety of foods and personal care products, 
and has received both US FDA and EU (E418) approval for these 
purposes.  
 Gellan gum is an anionic extracellular bacterial polysaccharide 
produced in high yield by the non-pathogenic strain 20 
Sphingomonas elodea2 (ATCC 31461, formerly classified as 
Pseudomonas elodea). It consists of tetrasaccharide repeat units 
containing β-D-glucose, β-D-glucuronic acid and α-L-rhamnose 
monomers in the molar ratio 2:1:13. In its native form, usually 
referred to as high-acyl GG (HAGG), O-acetate and L-glycerate 25 
substituents are attached to one glucose residue, with an average 
of 1 glycerate and 0.5 acetate substituents per repeat unit4 (Fig. 
1A). In most commercial products, however, these substituents 
are removed by alkali treatment to yield low-acyl GG (LAGG, 
Fig. 1B), which contains very few if any acyl groups. The 30 
average molecular mass of LAGG is ~ 2-5x105 Da. GG is sold 
commercially under a number of product names depending on the 
application area. For example, the CP Kelco company sells 
Gelzan™ as an alternative to agar for microbiological media. The 
LAGG in Gelzan™ has been extensively purified to remove any 35 
residual endotoxin material remaining after synthesis.  
 The usefulness of GG pertains largely to its gelation 
properties, which have been discussed in detail in a number of 
review articles1,7,8. Briefly, GG dissolves readily in water, 
adopting a disordered conformation (random coil) at higher 40 
temperatures (> ~ 40 °C) which subsequently undergoes a 
disordered-to-ordered transition on cooling. X-ray diffraction 
studies on GG fibres have shown that the ordered conformation is 
a threefold, left-handed, parallel double helix9. This 
conformational transition has been observed and characterised 45 
extensively by techniques including rheology10,11, light 
scattering12,13, nuclear magnetic resonance (NMR) 
spectroscopy14,15, and circular dichroism (CD) spectroscopy13. 
These studies have revealed that the conformational transition 
temperature is dependent on a number of factors including the 50 
concentration and molecular weight of the polymer 16,17, cation 
concentration18,19 and pH20. While helical ordering at low 
temperatures may impart weak gel characteristics, the formation 
of a true hydrogel network is achieved through cation-mediated 
association of helices21,22 (Fig. 2). This association can be 55 
facilitated through either monovalent or divalent cations, 
although divalent cations produce stronger gels. Divalent cations 
act as direct bridges by site binding between pairs of carboxyl 
groups, while monovalent cations induce aggregation by 
suppressing electrostatic repulsions23. 60 
  
Fig. 1. Structure of the tetrasaccharide repeat unit in commercially 
available high acyl (A) and low acyl (B) gellan gum, as well as 
methacrylated gellan gum (C). A and B reproduced from reference 5, C 
reproduced from reference 6. 65 
The presence of the acyl substituents in HAGG does not change 
 
the overall helical structure, but changes the binding (cross-
linking) sites for the cations. It has been suggested that this 
change is responsible for the loss of cation-mediated aggregation 
between the HAGG helices. The result of this difference in 
aggregation behaviour is that LAGG forms hard (non-elastic) and 5 
brittle gels, whereas HAGG gels are soft (elastic) and non-
brittle1. 
Fig. 2. Schematic model of the conformational transitions and gelation of 
low acyl gellan gum through temperature changes with and without 
added cations. Adapted from reference 1. 10 
 Aside from its widespread application in food and cosmetics, 
GG’s unique suspending (dispersing), gelation and rheological 
properties have been utilized for biomedical purposes and in the 
processing of conducting fillers. For example, GG has been 
employed as a versatile encapsulating agent and active ingredient 15 
in numerous controlled drug delivery systems for nasal, ocular, 
gastric and colonic drug delivery applications24-33, as implants for 
insulin delivery34 and for wound healing applications35-38. In 
addition, we and others have used GG to disperse carbon 
nanotubes in aqueous media which enables subsequent 20 
processing into useful architectures by film casting39-42, vacuum 
filtration43, inkjet printing44 and extrusion printing45. GG has also 
been used as a dopant in the synthesis of polypyrrole electrode 
coatings for neural devices46 and to stabilise nanoparticles47.  
 The remainder of this article explores an emerging new 25 
direction for GG as a material for applications in tissue 
engineering (TE). In particular, we have highlighted gellan gum 
which has been modified either chemically (covalent 
functionalisation) or physically (e.g. interpenetrating network 
formation).  This is a multidisciplinary field that draws primarily 30 
on principles from the engineering and life sciences to develop 
biological substitutes that restore, maintain or improve tissue 
function48. Typically, this is achieved through some combination 
of living cells with synthetic or natural biomaterials. These 
biomaterials act as a surrogate for the natural extracellular matrix 35 
(ECM), with the primary aim of engineering functional constructs 
that recapitulate the complex characteristics of natural tissues and 
organs.  
2. Why consider gellan gum? 
Gelation of GG, as described previously, is preceded by a 40 
conformational transition from coil to double helix, and 
association of these helices in junction zones is facilitated 
through either monovalent or divalent cations. Consequently, GG 
hydrogels may be formed at low concentrations of divalent 
cations, or even in the presence of monovalent cations alone1. 45 
This could be advantageous in TE applications and it has been 
shown that GG can be crosslinked to form self-supporting 
hydrogel structures simply by the addition of standard cell culture 
media with no added ions49. In addition, GG formed a gel on 
contact with tear fluid50, which is advantageous for ophthalmic 50 
drug delivery. GG hydrogels are therefore also stable during 
long-term culture in standard media and do not suffer from 
unwanted dissolution due to ionic exchange51. In addition to these 
gelation properties, GG’s excellent optical clarity could prove 
advantageous in analysis of encapsulated cells7. It has been 55 
shown that GG scaffolds can be made porous using 
straightforward fabrication methods52. Furthermore, GG appears 
not to inhibit polymerase chain reaction (PCR) analysis53 and is 
suitable as an injectable material54-56. 
 A further attractive characteristic of GG for TE are the 60 
mechanical similarity to the elastic moduli of common tissue. The 
mechanical characteristics of GG depend on type (LAGG or 
HAGG) and concentration as well as the type and amount of 
physical cross-linker57. Other strategies involve methacrylation of 
the GG chain (Fig. 1C) followed by physical and/or chemical 65 
cross-linking58. These approaches can be used to tune the elastic 
modulus of GG hydrogels to that comparable with a wide range 
of human soft tissues such as muscle, liver and cartilage59. 
 Finally the degradation behaviour of GG can be controlled. 
There are a number of human enzymes such as lysozyme, 70 
amylase and trypsin which are known to degrade common 
polysaccharides60.  These enzymes are commonly found in tears, 
mucus, milk and the stomach and degrade polysaccharides 
through hydrolysis. It has been reported that the enzymatic 
degradation of GG containing hydrogels resulted in a mass loss of 75 
20% and 30% over 7 days with lysozyme and trypsin, 
respectively61. However, most studies with TE in mind have 
focussed on the degradation behaviour of GG in ionic solutions. 
For example, we recently investigated the mass loss of LAGG, 
HAGG and LAGG/HAGG blended hydrogels for up to 168 days 80 
in phosphate buffered saline (PBS, pH 7.4) at 37 °C 51. It was 
observed that all three types of gels degraded for 28 days and 
then did not degrade any further for the additional 140 days of the 
testing period. Mass loss was smallest for LAGG (5.3 ± 0.7 %), 
largest for HAGG (12.1 ± 0.6), and intermediate for the blend. 85 
The degradation behaviour of GG gels in culture media in the 
presence and absence of bone marrow cells has also been 
investigated using rheological measurements62. Other work using 
methacrylated LAGG has shown that the degradation rate (in 0.1 
mM NaOH, at 37 °C) can be influenced by the cross-linking 90 
mechanism, i.e. physical or combined physical and chemical58.  
3. Gellan gum in tissue engineering 
Smith and co-workers were the first group to demonstrate that 
GG hydrogels could be used to encapsulate viable mammalian 
cells49. They showed that GG could be crosslinked by the 95 
addition of cell culture media alone, owing to the gelation of GG 
at milliMolar concentrations of divalent cations which are present 
in most media formulations, to form self-supporting hydrogels 
(Fig. 3A). This enabled a mild encapsulation process for rat bone 
marrow cells (Fig 3B), which remained viable in the GG 100 
hydrogels for 21 days in culture. In our initial work on 
applications of GG to TE, hydrogels were produced with and 
without added CNTs and surface topographical features, and 
these were shown to support and guide the growth of L929 
 
fibroblast cells54. 
Fig. 3. (A) GG hydrogel cylinders produced by extruding 1% w/v GG 
solution into culture medium. (B) Calcein-stained rat bone marrow cells 
in GG hydrogel after 10 days in culture. Figures adapted from reference 
49. (See web version of this article for a colour version of this figure.) 5 
 Reis and co-workers at the 3B’s Research Group (University 
of Minho, Portugal) have explored the use of GG hydrogels in TE 
applications63-65. Chondrocytes were shown to remain viable 
when encapsulated in GG hydrogels63 and exhibited ECM 
production when implanted subcutaneously in nude mice66. 10 
Injectable delivery of these chondrocyte-laden gels was also 
investigated, taking advantage of the ability of GG to form a gel 
under physiological conditions67. GG hydrogels were also used to 
encapsulate oligodendrocyte-like cells within the centre of a 
tubular structure fabricated by 3D extrusion printing of starch68. 15 
This group has also demonstrated that GG can be methacrylated 
to introduce the possibility of photo-initiated crosslinking58, thus 
enhancing the range of mechanical and degradation properties 
that can be tailored in GG hydrogels. These materials have been 
studied for application as cellular or acellular artificial nucleus 20 
pulposus implants in the treatment of intervertebral disk 
degeneration69-71. Du and co-workers took an alternative route to 
chemical crosslinking by thiolation of GG to produce a stable 
injectable system55.  
 Wang’s group at Nanyang Technological University 25 
(Singapore) have also implemented GG hydrogels in cartilage 
engineering. The gelation temperature of GG hydrogels was 
optimised (to 37.5 °C) by controlling the GG molecular weight 
through oxidative cleavage72. Chondrocytes encapsulated in these 
hydrogels showed expression levels of collagen that 30 
outperformed cells in agarose. Furthermore, rabbit mesenchymal 
stem cells encapsulated in GG hydrogels and cultured in 
chondrogenic medium were shown to express both chondrocytic 
genes and cartilaginous matrix73. Lee and co-workers also 
attempted to optimise the physical parameters of GG hydrogels 35 
for cartilage applications by blending low-acyl and high-acyl 
GG74. They found that increasing the HAGG:LAGG ratio 
resulted in a decrease in the gel’s stiffness, and that gels of 2% 
(w/v) LAGG were most suitable for fibro-cartilage applications. 
Blending GG with other types of biomolecules (e.g. 40 
polysaccharides and enyzmes) for TE applications have also been 
considered75-81.  
4. Modified gellan gum 
GG is a relatively bio-inert material. This has been demonstrated 
through the lack of cell infiltration and angiogenesis observed 45 
when implanting GG hydrogels in vivo70 and through evaluation 
of the behaviour/response of anchorage dependent cells 
encapsulated in GG hydrogels58,68. Thus application has so far 
been largely limited to anchorage-independent cells like 
chondrocytes63,72. Therefore, in order to function as a useful 50 
artificial ECM for anchorage-dependent cell types, GG must be 
modified. Previously, GG microspheres produced by a water-in-
oil emulsion process have been covalently functionalised with 
gelatin through redox-mediated crosslinking to encourage the 
attachment of human dermal fibroblasts and human fetal 55 
osteoblasts82. Photo-crosslinkable variants of both GG and gelatin 
have also been combined in a novel double-network hydrogel 
with enhanced mechanical properties6. More recently, GG 
hydrogels were modified with RGD-containing peptides to 
enhance interaction with encapsulated neural stem/progenitor 60 
cells83 (Fig. 4). Another interesting development is the 
modification of GG with surfactants to function as a bio-ink for 
cell printing applications84. 
Fig. 4. Morphology and dispersion of neural stem/progenitor cells (NSPCs) 
on the gellan gum hydrogel modified with the cell-adhesive peptide (GG-65 
GRGDS). Confocal analyses revealed substantial differences in NSPC 
morphology when cultured either (A) on the surface or (B) encapsulated 
within the GG-GRGDS vs. unmodified GG gel. Cell spreading and visible 
cytoplasmatic extensions were only observed in the GG-GRGDS. In the 
unmodified GG, NSPCs proliferated as neurospheres. The cytoplasm was 70 
stained with the anti-F-actin/phalloidin (red) and nuclei counterstained 
 
with DAPI (blue). (See web version of this article for a colour version of 
this figure.) Reproduced from reference 83. 
Although it is straightforward to prepare GG hydrogels with 
elastic moduli similar to that of tissue, matching the toughness 
and load tolerance of mammalian tissue is not. For example, 5 
LAGG and HAGG gels can be prepared with elastic moduli (kPa 
range) similar to that of liver, fat, muscle or cartilage58,85. But the 
compressive stress at failure of these gels (kPa range) is orders of 
magnitude lower than tissues such as cartilage (MPa range)58,86. 
In other words GG hydrogels are mechanically weak, which is a 10 
generally recognised drawback of hydrogel materials under 
consideration for tissue engineering87.   
 A number of strategies have been adopted to address the 
mechanical weakness and/or load intolerance. Hydrogels based 
on chemically/physically cross-linked methacrylated GG resulted 15 
in improvements in the magnitude of compressive stress at failure 
(up to 0.9 MPa)58. It is not known if these gels would be able to 
recover from damage (load tolerance). Progress towards the latter 
has been made by building on the pioneering research on 
toughening gels by J.P. Gong88-90. These gels exhibit excellent 20 
mechanical performance such as, for example, compressive stress 
at failure values of up to 60 MPa90. The toughening of hydrogels 
is achieved using an interpenetrating polymer network (IPN) 
approach which results in so-called “double network” (DN) 
hydrogels with mechanical properties that are significantly 25 
improved compared with either one of the parent networks88-90. 
The two polymer networks in the DN approach are chemically 
(covalently) cross-linked, and the toughening mechanism arises 
from efficient energy dissipation due to fragmentation of the first 
(brittle) network thereby allowing the second (ductile) network to 30 
facilitate large deformations89,90. The DN approach has also been 
adopted for methacrylated GG in combination with methacrylated 
gelatin91. The resulting DN gels exhibited compressive stress at 
failure values of close to 7 MPa. DN gels are extremely tough, 
but due to the irreversible, permanent fracture of the chemical 35 
cross-links89,90 DN gels are not able to recovery from significant 
loading and have poor fatigue resistance.  
 Recently, it has been demonstrated that preparing IPN gels 
combining one network with reversible physical (non-covalent) 
bonds and one network with irreversible covalent networks 40 
results in gels that are tough but can recover from damage92-94. 
For example, it was demonstrated that hydrogels consisting of 
ionically cross-linked LAGG and covalently cross-linked 
poly(acrylamide) exhibited double network behaviour, i.e. 
improved mechanical properties compared to their respective 45 
single network hydrogels93. These so-called ionic-covalent 
entanglement hydrogels exhibited self-recovery of 53 ± 4 % 
within 80 min from the first compressive cycle (Fig. 5).  
5. Recommendations 
This article has highlighted modified gellan gum as a suitable 50 
material for tissue engineering applications. The remaining 
challenges are to prepare gellan gum materials that achieve one or 
all of the following (depending on the intended application): (i) 
improved toughness and extensibility so that these gels can 
function as tissue mimics. In particular, gels that have the 55 
appropriate mechanical characteristics of mammalian tissue so 
that they can recover from strain and absorb impact without 
permanent damage (this is important for cartilage tissue 
engineering); (ii) attachment and function of encapsulated 
anchorage-dependent cells; and (iii) suitable degradation 60 
behaviour (important for regenerative tissue engineering). In 
conclusion, it is clear that modified gellan gum offers great 
opportunities as a material for tissue engineering, but a number of 
challenges remain to be addressed. 
Fig. 5. The dissipated energy (Uhist, hysteresis of loading/unloading cycle 65 
2) and recovery as a function of recovery time between cycles 1 and 2 
for hydrogels consisting of ionically cross-linked LAGG and covalently 
cross-linked poly(acrylamide). The line is a fit to the data to guide the 
reader’s eye. Figure reproduced from reference 93. 
Acknowledgements 70 
The University of Wollongong and the Australian Research 
Council (Centre of Excellence, Laureate and Future Fellowship 
programs) are thanked for their support. 
Notes and references 
a Soft Materials Group, School of Chemistry, University of Wollongong, 75 
Wollongong, NSW 2522, Australia. Tel: +61 24221 3155; E-mail: 
panhuis@uow.edu.au 
b Intelligent Polymer Research Institute, ARC Centre of Excellence for 
Electromaterials Science, AIIM Facility, University of Wollongong, 
Wollongong, NSW 2522, Australia; E-mail: gwallace@uow.edu.au 80 
 
1. E. R. Morris, K. Nishinari, and M. Rinaudo, Food Hydrocolloids, 
2012, 28, 373–411. 
2. T. J. Pollock, Journal of General Microbiology, 1993, 139, 1939–
1945. 85 
3. P. Jansson and B. Lindberg, Carbohydrate Research, 1983, 124, 
135–139. 
4. A. J. Jay, I. J. Colquhoun, M. J. Ridout, G. J. Brownsey, V. J. Morris, 
A. M. Fialho, J. H. Leitão, and I. Sá-Correia’, Carbohydrate 
Polymers, 1998, 35, 179–188. 90 
5. R. Mao, J. Tang, and B. G. Swanson, Carbohydrate Polymers, 2000, 
41, 331–338. 
6. H. Shin, B. D. Olsen, and A. Khademhosseini, Biomaterials, 2012, 
33, 3143–3152. 
7. I. Giavasis, L. M. Harvey, and B. McNeil, Critical Reviews in 95 
Biotechnology, 2000, 20, 177–211. 
8. A. M. Fialho, L. M. Moreira, A. T. Granja, A. O. Popescu, K. 
Hoffmann, and I. Sá-Correia, Applied Microbiology and 
Biotechnology, 2008, 79, 889–900. 
9. R. Chandrasekaran and A. Radha, Trends in Food Science and 100 
Technology, 1995, 6, 143–148. 
10. E. Miyoshi, Carbohydrate Polymers, 1996, 30, 109–119. 
11. M. Milas, X. Shi, and M. Rinaudo, Biopolymers, 1990, 30, 451–464. 
12. E. Ogawa, Macromolecules, 1996, 29, 5178–5182. 
13. E. Ogawa, H. Matsuzawa, and M. Iwahashi, Food Hydrocolloids, 105 
2002, 16, 1–9. 
 
14. M. Bosco, S. Miertus, M. Dentini, and A. L. Segre, Biopolymers, 
2000, 54, 115–26. 
15. M. Milas, Carbohydrate Polymers, 1996, 30, 177–184. 
16. E. Ogawa, R. Takahashi, H. Yajima, and K. Nishinari, Biopolymers, 
2005, 79, 207–217. 5 
17. E. Ogawa, R. Takahashi, H. Yajima, and K. Nishinari, Food 
Hydrocolloids, 2006, 20, 378–385. 
18. J. Horinaka, K. Kani, Y. Itokawa, E. Ogawa, and Y. Shindo, 
Biopolymers, 2004, 75, 376–383. 
19. K. Kani, J. Horinaka, and S. Maeda, Carbohydrate Polymers, 2005, 10 
61, 168–173. 
20. J. Horinaka, K. Kani, Y. Hori, and S. Maeda, Biophysical Chemistry, 
2004, 111, 223–227. 
21. V. Crescenzi, M. Dentini, T. Coviello, and R. Rizzo, Carbohydrate 
Research, 1986, 149, 425–432. 15 
22. H. Grasdalen and O. Smidsrod, Carbohydrate Polymers, 1987, 7, 
371–393. 
23. E. Morris, Carbohydrate Polymers, 1996, 30, 165–175. 
24. S. A. Agnihotri, S. S. Jawalkar, and T. M. Aminabhavi, European 
Journal of Pharmaceutics and Biopharmaceutics, 2006, 63, 249–261. 20 
25. B. Jansson, H. Hägerström, N. Fransén, K. Edsman, and E. Björk, 
European Journal of Pharmaceutics and Biopharmaceutics, 2005, 
59, 557–564. 
26. Y. Sultana, M. Aqil, and A. Ali, Drug Delivery, 2006, 13, 215–219. 
27. F. Kedzierewicz, C. Lombry, R. Rios, M. Hoffman, and P. Maincent, 25 
International Journal of Pharmaceutics, 1999, 178, 129–136. 
28. A. Gal and A. Nussinovitch, Journal of Pharmaceutical Sciences, 
2007, 96, 168–178. 
29. S. C. Kumar, C. S. Satish, and H. G. Shivakumar, Journal of 
Macromolecular Science, Part A, 2008, 45, 643–649. 30 
30.  P. Pahuja, S. Arora, and P. Pawar, Expert Opinion on Drug Delivery, 
2012, 9, 837-861. 
31. S. Maiti, S. Ghosh, R. Mondol, S. Ray, and B. Sa, Journal of 
Microencapsulation, 2012, 29, 747-. 
32. A. Geethalakshmi, R. Karki, S.K. Jha, D.P. Venkatesh, and B. Nikunj, 35 
Current Drug Delivery, 2012, 9, 197. 
33. Y. Liu, J. Liu, X. Zhang, R. Zhang, Y. Huang, and C. Wu, AAPS 
PharmSciTech., 2010, 11, 610-620. 
34. J. Li, K. Kamath, and C. Dwivedi, Journal of Biomaterials 
Applications, 2001, 15, 321–343. 40 
35. K.A. Mat Amin and M. in het Panhuis, Carbohydrate Polymers, 2011, 
86, 352-358. 
36. K.A. Mat Amin, Kerry J. Gilmore, Jake Matic, Stephen Poon, Mark J. 
Walker, Mark R. Wilson and M. in het Panhuis, Macromolecular 
Bioscience, 2012, 12, 374-382. 45 
37. C. Cencetti, et al., Carbohydryte Polymers, 2012, 90, 1362-1370. 
38. M.W. Lee, H.F. Tsai, S.M. Wen, and C.H. Huang, Carbohydrate 
Polymers, 2012, 90, 1132-1138. 
39. C. J. Ferris and M. in het Panhuis, Soft Matter, 2009, 5, 1466-1473. 
40. N. Songmee, P. Singjai, and M. in het Panhuis, Nanoscale, 2010, 2, 50 
1740–1745. 
41. L. Lu and W. Chen, ACS nano, 2010, 4, 1042–1048. 
42. J. P. Ferrance, A. R. Juriani, J. W. Pettit, and K. E. Meissner, Journal 
of Nanoelectronics and Optoelectronics, 2011, 6, 102–110. 
43. J. Boge, L. J. Sweetman, M. in het Panhuis, and S. F. Ralph, Journal 55 
of Materials Chemistry, 2009, 19, 9131-9140. 
44. M. in het Panhuis, A. Heurtematte, W. R. Small, and V. N. Paunov, 
Soft Matter, 2007, 3, 840-843. 
45. G. C. Pidcock and M. in het Panhuis, Advanced Functional 
Materials, 2012, 22, 4790-4800. 60 
46. T. M. Higgins, S. E. Moulton, K. J. Gilmore, G. G. Wallace, and M. 
in het Panhuis, Soft Matter, 2011, 7, 4690-4695. 
47. S. Dhar, P. Murawala, A. Shiras, V. Pokharkar, and B.L. Prasad, 
Nanoscale, 2012, 4, 563-567. 
48. R. Langer and J. P. Vacanti, Science, 1993, 260, 920–926. 65 
49. A. M. Smith, R. M. Shelton, Y. Perrie, and J. J. Harris, Journal of 
Biomaterials Applications, 2007, 22, 241–254. 
50. I. D. Rupenthal, C. R. Green, and R. G. Alany, International Journal 
of Pharmaceutics, 2011, 411, 69–77. 
51. D. A. De Silva, L. A. Poole-Warren, P. J. Martens, and M. in het 70 
Panhuis, Journal of Applied Polymer Science, accepted for 
publication. 
52. J. Peña, J. Román, M. V. Cabañas, and M. Vallet-Regí, Acta 
Biomaterialia, 2010, 6, 1288-1296. 
53. P. M. Rath and D. Schmidt, Journal of Medical Microbiology, 2001, 75 
50, 108–109. 
54. C. J. Ferris and M. in het Panhuis, Soft Matter, 2009, 5, 3430–3437. 
55. H. Du, P. Hamilton, M. Reilly, and N. Ravi, Macromolecular 
Bioscience, 2012, 12, 952–61. 
56. J.T. Oliveira, L.S. Gardel, T. Rada, L. Martins, M.E. Gomes, and R.L. 80 
Reis, Journal of Orthopedic Research, 2010, 28, 1193-1199. 
57. J. Tang, Carbohydrate Polymers, 1996, 29, 11–16. 
58. D. F. Coutinho, S. V. Sant, H. Shin, J. T. Oliveira, M. E. Gomes, N. 
M. Neves, A. Khademhosseini, and R. L. Reis, Biomaterials, 2010, 
31, 7494–7502. 85 
59. D. E. Discher, P. Janmey, and Y.-L. Wang, Science, 2005, 310, 
1139–1143. 
60. R. H. Garrett and C. M. Grisham, Biochemistry, Brooks Cole, 
Belmont, 2007. 
61. S. Suri and R. Banerjee, Journal of Biomedical Materials Research. 90 
Part A, 2006, 79, 650–664. 
62. S.H. Jahromi, L.M. Grover, J.Z. Paxton, and A.M. Smith, Journal of 
the Mechanical Behaviour of Biomedical Materials, 2011, 4, 1157-
1166. 
63. J. T. Oliveira, L. Martins, R. Picciochi, P. B. Malafaya, R. A. Sousa, 95 
N. M. Neves, J. F. Mano, and R. L. Reis, Journal of Biomedical 
Materials Research Part A, 2010, 93A, 852–863. 
64. C. Correia, et al, Tissue Engineering Part A, 2012, 18, 1979-1991. 
65. A.L. Oliveira, et al., Journal of Materials Science Materials in 
Medicine, 2012, 23, 2821-2830. 100 
66. J. T. Oliveira, T. C. Santos, L. Martins, M. A. Silva, A. P. Marques, 
A. G. Castro, N. M. Neves, and R. L. Reis, Journal of Tissue 
Engineering and Regenerative Medicine, 2009, 3, 493–500. 
67. J. T. Oliveira, T. C. Santos, L. Martins, R. Picciochi, A. P. Marques, 
A. G. Castro, N. M. Neves, J. F. Mano, and R. L. Reis, Tissue 105 
Engineering. Part A, 2010, 16, 343–353. 
68. N. A. Silva, A. J. Salgado, R. A. Sousa, J. T. Oliveira, A. J. Pedro, H. 
Leite-Almeida, R. Cerqueira, A. Almeida, F. Mastronardi, J. F. 
Mano, N. M. Neves, N. Sousa, and R. L. Reis, Tissue Engineering. 
Part A, 2010, 16, 45–54. 110 
69. J. Silva-Correia, J. M. Oliveira, S. G. Caridade, J. T. Oliveira, R. A. 
Sousa, J. F. Mano, and R. L. Reis, Journal of Tissue Engineering and 
Regenerative Medicine, 2011, 5, e97-e107  
70. J. Silva-Correia, V. Miranda-Gonçalves, A. J. Salgado, N. Sousa, J. 
M. Oliveira, R. M. Reis, and R. L. Reis, Tissue Engineering. Part A, 115 
2012, 18, 1203–1212. 
71. D. R. Pereira, J. Silva-Correia, S. G. Caridade, J. T. Oliveira, R. A. 
Sousa, A. J. Salgado, J. M. Oliveira, J. F. Mano, N. Sousa, and R. L. 
Reis, Tissue Engineering. Part C, Methods, 2011, 17, 961–972. 
72. Y. Gong, C. Wang, R. C. Lai, K. Su, F. Zhang, and D. Wang, Journal 120 
of Materials Chemistry, 2009, 19, 1968. 
73. J. Fan, Y. Gong, L. Ren, R. R. Varshney, D. Cai, and D.-A. Wang, 
Acta Biomaterialia, 2010, 6, 1178–1185. 
74. H. Lee, S. Fisher, M. S. Kallos, and C. J. Hunter, Journal of 
Biomedical Materials Research. Part B, Applied biomaterials, 2011, 125 
98B, 238–245. 
75. G. Ciardelli, Biomacromolecules, 2005, 6, 1961-1976. 
76. F. Bertoni, N. Barbani, P. Giusti and G. Ciardelli, Biotechnology 
Letters, 2006, 28, 697-702. 
77. M.G. Cascone, N. Barbani, C. Cristallini, P. Giusti, G. Ciardelli, and 130 
L. Lazzeri, Journal of Biomaterials Science Polymer Edition, 2001, 
12, 267-281. 
78. T. Douglas, et al., Tissue Engineering Regenerative Medicine, 2013, 
doi: 10.1002/term.1616.  
79. J.S. Patil, M.V. Kamalapur, S.C. Marapur, and S.S. Shiralshetti, 135 
Indian Journal of Pharmaceutical Science, 2011, 73, 504-509. 
80. D.F. Coutinho, A.F. Ahari, N.N. Kachouie, M.E. Gomes, N.M. 
Neves, R.L. Reis, and A. Khademhosseini, Biofabrication, 2012 4, 
035003. 
 
81. N. Barbani, et al., Journal of Materials Science Materials in 
Medicine, 2012, 23, 51-61. 
82. C. Wang, Y. Gong, Y. Lin, J. Shen, and D.-A. Wang, Acta 
Biomaterialia, 2008, 4, 1226–1234. 
83. N. A Silva, M. J. Cooke, R. Y. Tam, N. Sousa, A. J. Salgado, R. L. 5 
Reis, and M. S. Shoichet, Biomaterials, 2012, 33, 6345–6354.  
84. C.J. Ferris, S. Beirne, D. McCallum, K.J. Gilmore, G.G. Wallace, and 
M. in het Panhuis, Biomaterials Science, 2013, 1, 224-230 
85.  D.E. Discher, D.J. Mooney, and P.W. Zandstra, Science, 2009, 324, 
1673-1677. 10 
86. A.J. Kerin, M.R. Wisnom, and M.A. Adams,  Engineering in 
Medicine, 1998, 212, 273-280. 
87.  T. Billiet et al, Biomaterials, 2012, 33, 6020-6041.  
88. J. P. Gong, Y. Katsuyama, T. Kurokawa, and  Y. Osada, Advanced 
Materials, 2003, 15, 1155-1158. 15 
89.  J. P. Gong, Soft Matter, 2010, 6, 2583-2590. 
90. M.A. Haque, T. Kurokawa, and J.P. Gong, Polymer, 2012, 53, 1805-
1822.  
91. H. Shin, B. D. Olsen, and A. Khademhosseini, Biomaterials, 2012, 
33, 3143-3152. 20 
92. M.A. Haque, T. Kurokawa, G. Kamita, and J.P. Gong, 
Macromolecules, 2011, 44, 8916-8924. 
93. S.E. Bakarich, G.C. Pidcock, P. Balding, L. Stevens, P. Calvert, and 
M. in het Panhuis, Soft Matter, 2012, 8, 9985-9988. 
94. J.-Y. Sun, X. Zhao, W. R. K. Illeperuma, O. Chaudhuri, K. H. Oh, D. 25 
J. Mooney, J. J. Vlassak, Z. Suo, Nature, 2012, 489, 133–136. 
 
 
